Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer

• Status: Recruiting
• Trial end date: 2022-07-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore the efficacy of adjuvant radiotherapy for D2 resected gastric cancer

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huazhong University of Science and Technology

Criteria

Inclusion Criteria:

1. Aged 18-75；

2. Had histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction；

3. ECOG 0-1；

4. Subjects has to voluntarily join the study and sign the Informed Consent Form for the study;

5. D2 and R0 resection;

6. Locally advanced (UICC stage, T4, N2, N3) gastric cancer after surgery;

7. More than 15 lymph nodes;

8. Adequate organ function as defined below: Hematologic ANC ≥ 2*109/L, Platelets ≥ 100*109/L, AST and ALT ≤ 2.5×ULN, TBIL ≤ 1.5×ULN.

Exclusion Criteria:

1. Previous radiotherapy or chemotherapy；

2. Inadequate organ function;

3. Pregnant or lactating women or women of childbearing potential.